



1FW

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF : Miller et al.
FOR : **POLYCATIONIC DERIVATIVES AS
TRANSFECTION AGENTS**
SERIAL NO. : 10/770,294
FILED : February 2, 2004
ART UNIT : 1615
ATTORNEY DOCKET NO. : YOUZ 2 00059

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(c)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with 37 C.F.R. §§ 1.56, 1.97, 1.98 and MPEP § 609, Applicant submits the following Disclosure Statement concerning art of which the Applicant is aware. A copy of PTO-1449 is enclosed herewith.

This Information Disclosure Statement is not intended to constitute an admission that any patent, publication or other information referred to herein or submitted herewith is "prior art" for this invention unless specifically designated as such.

In accordance with 37 C.F.R. §1.97(g) and (h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

Under § 1.98(a)(3), no concise explanation of relevance is required for information that is in the English language.

5,767,099 – Harris et al.

WO 96/10038

Other Art:

Moradpour et al., Biochemical and Biophysical Research Communications,
Vol. 221, pp. 82-88; 04/1996

CERTIFICATE OF MAILING

I hereby certify that this **INFORMATION DISCLOSURE STATEMENT** is being deposited with the United States Postal Service in an envelope addressed to the Commissioner for Patents, Alexandria, VA 22313-1450, on July 21, 2004.

By: _____

Georgene B. Sonntag

Under Rule 97(b)(3), this information disclosure statement is being filed before the mailing date of a first Office Action on the merits and accordingly no fee is necessary.

OG Notice August 5, 2003


The Office has waived the requirement under 37 CFR §1.98(a)(2)(i) that copies of cited U.S. patent documents be submitted in connection with all applications filed on or after June 30, 2003. As such, copies of the U.S. patent documents cited herein have not been included.

It is respectfully requested that the attached documents be considered and officially cited in examination of this application.


Respectfully submitted,

FAY, SHARPE, FAGAN,
MINNICH & McKEE, LLP

Date: July 21, 2004



Scott A. McCollister
Reg. No. 33,961
1100 Superior Avenue, Seventh Floor
Cleveland, Ohio 44114-2518
(216) 861-5582



Subst. Form PTO-1449

Atty. Docket No.: YOU 2 00059-2

Serial No.: 10/770,294

APPLICANT'S(S') INFORMATION
DISCLOSURE STATEMENT

Applicant(s): Miller et al.

Filing Date: February 2, 2004

Group: 1615

U.S. PATENT DOCUMENTS

Initial*		Document No.	Date	Name	Class	Subcl.	Filing Date
	AA	5,767,099	10/1995	Harris et al.			
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Subcl.	Translation?
	AL	WO 96/10038	4/1996	PCT			
	AM						
	AN						
	AO						
	AP						
	AQ						

OTHER ART

	AR	Moradpour et al., Biochemical and Biophysical Research Communications, Vol. 221, pp. 82-88; 04/1996
	AS	
	AT	
	AU	
	AV	
	AW	

Examiner:

Date Considered:

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.